SecBot SecBot
144 ·Filed Aug 13, 2026

DYN

Dyne Therapeutics, Inc.
BEARISH
Impact 6/10
Horizondays Processed3mo ago SEC0001628280-26-056843
Actionable Insight ▼ Bearish

The simultaneous Form 144 filings by a major venture capital insider (Atlas Venture) and a director (John Cox) signal a strong bearish sentiment from those closest to the company. Monitor for any subsequent Form 4 filings confirming the sales, and watch for any negative pipeline or regulatory news that may have prompted this insider activity.

DirectionBearish
Confidencehigh
Horizondays

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$25.70
T+0 close · Aug 13, 2026 · via day close
Latest settled
−26.96%
T+60 · $18.77
Vs SPY
−24.16%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 14 $25.70entry
  2. T+1 · 3mo ago +1.75%α +2.22% · $26.15
  3. T+5 · 3mo ago +1.56%α +2.92% · $26.10
  4. T+20 · 2mo ago −27.94%α −25.95% · $18.52
  5. T+60 · 8d ago −26.96%α −24.16% · $18.77
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Atlas Venture Fund XI, L.P., a major venture capital insider, filed a Form 144 on August 13, 2026, indicating intent to sell 268,354 shares of Dyne Therapeutics (DYN) with an approximate market value of $7.0 million. Separately, Director John Cox also filed a Form 144 on the same day, signaling a proposed sale. The Atlas Venture sale represents a significant insider liquidation by a founding investor, which is a bearish signal for the stock, especially given the company's pre-revenue status and reliance on pipeline catalysts. The batch of filings on the same day amplifies the negative sentiment, suggesting coordinated insider selling.

Key Facts

  • Atlas Venture Fund XI, L.P. filed Form 144 to sell 268,354 shares of DYN, valued at approximately $7.0 million based on the filing date.
  • Director John Cox also filed a Form 144 on the same day, indicating a proposed sale of an undisclosed number of shares.
  • The Atlas Venture sale represents a significant portion of their holdings, as they are a founding venture capital investor.
  • The filing date is August 13, 2026, with the proposed sale to occur on or after that date.
  • The company has a market cap of $4.9B and a 90% bullish analyst consensus, but is a pre-revenue biotech.

Financial Impact

Atlas Venture proposes to sell $7.0M worth of DYN common stock. Director John Cox's proposed sale amount is undisclosed.

dilutioninsider_selling

Risk Factors

  • Form 144 is an intent to sell; the actual sale may not occur or may be for a smaller amount.
  • The company is pre-revenue, making it highly sensitive to pipeline and regulatory catalysts, which could overshadow insider selling.
  • High short interest or a positive catalyst could lead to a short squeeze, counteracting the bearish signal.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
90% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (DYN), Batch item 10001628280-26-056843
Document: 0001628280-26-056843-index.html0001628280-26-056843
Document: 0001628280-26-056843.txt0001972481-26-000260
144 Filing (DYN), Batch item 40001628280-26-056843
Document: 0001628280-26-056843-index.html0001628280-26-056843
144 Filing (DYN), Batch item 60001972481-26-000260

Track record

54 reports on DYN

Performance horizon

11 of 15 bullish or bearish reports moved the stock their way by T+20. Best: +46.36% at T+60 after the May 20, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G Neutral 3/10 Entry $16.77 Now $16.70 −0.39% settles Dec 15
  2. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  3. Nov 13, 20263d ago 144 Neutral 2/10 Entry $17.16 Now $16.70 −2.68% settles Dec 15
  4. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  5. Nov 5, 202611d ago Press Release Neutral 5/10 Entry $17.36 Now $16.70 −3.80% settles Dec 4
  6. Oct 29, 202618d ago Institutional Cluster Neutral 2/10 Entry $17.04 Now $16.70 −2.00% settles Nov 27
  7. Oct 22, 202625d ago Press Release Neutral 2/10 Entry $15.62 Now $16.70 +6.91% settles Nov 20
  8. Oct 12, 20265w ago Institutional Cluster Mixed 4/10 Entry $15.96 to $18.62 Now $16.70 +4.64% ▲ +16.67% +19.93% vs SPY
  9. Sep 29, 20266w ago Press Release Bullish 7/10 Entry $16.11 to $16.94 Now $16.70 +3.66% ▲ +5.15% +4.23% vs SPY
  10. Sep 8, 20269w ago Insider Cluster Neutral 3/10 Entry $19.19 to $15.97 Now $16.70 −12.98% ▼ −16.78% −18.72% vs SPY
Showing 10 of 54

US Market Status

Market Closed · Opens Wed (10h 40m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 13, 2026